By Stephen Nakrosis
Mira Pharmaceuticals said it was planning to size its planned initial public offering at 1 million shares of common stock.
The company said it expected the offering to price between $6 and $8 per share.
The pharmaceutical company said it is working on developing and commercializing a new molecular synthetic THC analog to treat adult patients with anxiety and “cognitive decline typically associated with early-stage dementia.”
Mira said it applied to list on the Nasdaq Capital Market under the symbol MIRA.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
Read the full article here